Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Medical Decision Making

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   43895   clinical trials with a EudraCT protocol, of which   7301   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    64 result(s) found for: Medical Decision Making. Displaying page 1 of 4.
    1  2  3  4  Next»
    EudraCT Number: 2018-004829-82 Sponsor Protocol Number: GHREDECIDE Start Date*: 2019-04-16
    Sponsor Name:Linköping University
    Full Title: Effects of the appetite-inducing hormone ghrelin on decision making in healthy volunteers
    Medical condition: NA, healthy volunteers
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: SE (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2021-006581-20 Sponsor Protocol Number: HEMCML28 Start Date*: 2022-05-11
    Sponsor Name:Radboud univeristy medical centre
    Full Title: A patient guided dose reduction strategy of tyrosine kinase inhibitors in chronic myeloid leukaemia: a prospective, multi-centre, non-randomised non-inferiority study.
    Medical condition: Chronic myeloid leukaemia
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004851 10024296 Leukaemias chronic myeloid HLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2012-005246-38 Sponsor Protocol Number: 143660 Start Date*: 2013-05-13
    Sponsor Name:University of Oslo
    Full Title: The effects of methylphenidate on brain processes for decision making in adult attention deficit hyperactivity disorder
    Medical condition: Attention deficit hyperactivty disorder
    Disease: Version SOC Term Classification Code Term Level
    15.1 10037175 - Psychiatric disorders 10003736 Attention deficit/hyperactivity disorder PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: NO (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2008-002795-96 Sponsor Protocol Number: CBFH772A2201 Start Date*: 2008-12-11
    Sponsor Name:Novartis Pharma Services AG
    Full Title: A single center, phase I, partially blinded, placebo-controlled, first-in-man study to evaluate the safety, tolerability and Proof of Mechanism (PoM) of a single administration of BFH772 in healthy...
    Medical condition: Plaque psoriasis
    Disease: Version SOC Term Classification Code Term Level
    9.1 10037153 Psoriasis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2012-000725-41 Sponsor Protocol Number: CLI-107-15 Start Date*: 2013-01-22
    Sponsor Name:Cytheris S.A.
    Full Title: A randomized, placebo controlled, multicenter phase IIb study of human recombinant Interleukin-7 (CYT107) in HIV-related Progressive Multifocal Leukoencephalopathy.
    Medical condition: HIV-infected patients with Progressive Multifocal Leukoencephalopathy
    Disease: Version SOC Term Classification Code Term Level
    15.0 10021881 - Infections and infestations 10036807 Progressive multifocal leukoencephalopathy PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Prematurely Ended) ES (Ongoing) IT (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2021-000399-12 Sponsor Protocol Number: GPHIP_0202 Start Date*: 2021-04-16
    Sponsor Name:Grand Medical Pty Ltd
    Full Title: A Randomized, Open-Label, Multi-Centre, Phase 2a Study to Evaluate the Safety and Effect of STC3141 Continuous Infusion in Subjects with Severe COVID-19 Pneumonia
    Medical condition: severe pneumonia due to COVID-19
    Disease: Version SOC Term Classification Code Term Level
    23.1 10021881 - Infections and infestations 10084380 COVID-19 pneumonia PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2015-004826-32 Sponsor Protocol Number: 3121001 Start Date*: 2016-10-24
    Sponsor Name:Orion Corporation Orion Pharma
    Full Title: Safety and pharmacokinetics of ODM-207 in patients with selected advanced solid tumours: an open-label, non-randomised, uncontrolled, multicentre, first-in-human study with cohort expansion
    Medical condition: Advanced Solid Tumours
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10065143 Malignant solid tumour LLT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) FI (Completed) ES (Completed) FR (Completed)
    Trial results: View results
    EudraCT Number: 2010-023576-10 Sponsor Protocol Number: CL3-20098-083 Start Date*: 2011-06-06
    Sponsor Name:Institut de Recherches Internationales Servier
    Full Title: Early effect of agomelatine on general interest in outpatients with Major Depressive Disorder. A 12-week, randomized, double-blind, multicentre study with parallel groups: agomelatine (25mg/day giv...
    Medical condition: Major Depressive Disorder
    Disease: Version SOC Term Classification Code Term Level
    19.0 10037175 - Psychiatric disorders 10057840 Major depression PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: RO (Completed)
    Trial results: View results
    EudraCT Number: 2019-000821-37 Sponsor Protocol Number: O3NPIQ Start Date*: 2019-12-10
    Sponsor Name:Bernardino Clavo - Hospital Universitario de G. C. Dr. Negrín
    Full Title: Effectiveness and cost-effectiveness of Ozone therapy in patients with pain secondary to chemotherapy-induced peripheral neuropathy. Randomized, triple-blind clinical trial.
    Medical condition: Pain secondary to chemotherapy-induced peripheral neuropathy.
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004852 10079545 Chemotherapy induced peripheral neuropathy LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2010-022529-14 Sponsor Protocol Number: WC25501 Start Date*: 2011-02-04
    Sponsor Name:F.Hoffmann-La Roche
    Full Title: A phase III, double-blind, randomized, placebo-controlled, multi-center study evaluating the efficacy and safety of dalcetrapib on lipids, lipoproteins, apolipoproteins and markers of CV risk in pa...
    Medical condition: Coronary Heart Disease
    Disease: Version SOC Term Classification Code Term Level
    14.0 10007541 - Cardiac disorders 10068617 Coronary heart disease LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Completed) GB (Completed) NL (Completed)
    Trial results: Removed from public view
    EudraCT Number: 2019-002587-28 Sponsor Protocol Number: 2019-5165 Start Date*: 2020-02-25
    Sponsor Name:Radboudumc
    Full Title: ABSORB 2:An exploratie study determining the oral antibiotic drug absorption in patients with short bowel syndrome.
    Medical condition: short bowel syndrome, home parenteral nutrition
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed)
    Trial results: View results
    EudraCT Number: 2012-005078-70 Sponsor Protocol Number: ACTICCA-1 Start Date*: 2014-01-16
    Sponsor Name:University Medical Center Hamburg-Eppendorf
    Full Title: Adjuvant chemotherapy with gemcitabine and cisplatin compared to standard of care after curative intent resection of cholangiocarcinoma and muscle invasive gallbladder carcinoma (ACTICCA-1 trial) ...
    Medical condition: Cholangiocarcinoma and gallbladder carcinoma
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10017620 Gallbladder carcinoma LLT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10008593 Cholangiocarcinoma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Restarted) NL (Ongoing) GB (GB - no longer in EU/EEA) DK (Completed) AT (Ongoing) IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2007-005103-18 Sponsor Protocol Number: NC20971 Start Date*: 2008-03-21
    Sponsor Name:F.Hoffmann-La Roche Ltd.
    Full Title: A phase III, double-blind, randomized placebo-controlled study, to evaluate the effects of RO4607381 on cardiovascular (CV) risk in stable CHD patients, with a documented recent Acute Coronary Synd...
    Medical condition: Stable CHD patients, with a documented recent Acute Coronary Syndrome (ACS)
    Disease: Version SOC Term Classification Code Term Level
    9.1 10007649 Cardiovascular disorder LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed) HU (Prematurely Ended) GB (Prematurely Ended) CZ (Prematurely Ended) AT (Prematurely Ended) NL (Prematurely Ended) SK (Completed) ES (Prematurely Ended) IE (Prematurely Ended) DK (Prematurely Ended) DE (Prematurely Ended) SE (Prematurely Ended) BE (Prematurely Ended) IT (Prematurely Ended) FI (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2018-000201-24 Sponsor Protocol Number: O3Cardio Start Date*: 2018-08-01
    Sponsor Name:Bernardino Clavo - Hospital Dr. Negrín
    Full Title: Effectiveness and cost-effectiveness of Ozone therapy in patients with ischemic heart disease refractory to medical and surgical treatment: Randomized, triple-blind clinical trial.
    Medical condition: Ischemic heart disease refractory to medical and surgical treatment.
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004849 10019279 Heart failure LLT
    20.0 100000004849 10055224 Cardiac ischemia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2018-003271-35 Sponsor Protocol Number: KU-AIM-01-2018 Start Date*: 2019-01-07
    Sponsor Name:University of Copenhagen
    Full Title: STUDY OF ATTENTION AND IMPULSIVITY IN HEALTHY HUMAN VOLUNTEERS
    Medical condition: Attentional deficits and impulsive behaviour. These symptoms are common in attention deficit hyperactivity disorder, but also other conditions affecting the central nervous system such as Alzheimer...
    Disease: Version SOC Term Classification Code Term Level
    20.0 10022891 - Investigations 10022891 Investigations SOC
    Population Age: Adults Gender: Male, Female
    Trial protocol: DK (Completed)
    Trial results: View results
    EudraCT Number: 2020-005492-12 Sponsor Protocol Number: BDTX-189-01 Start Date*: 2021-05-27
    Sponsor Name:Black Diamond Therapeutics, Inc.
    Full Title: MasterKey-01: A Phase 1/2, Open-label, Two-part, Multicenter Study to Assess the Safety, Tolerability, Pharmacokinetics, and Antitumor Activity of BDTX-189, an Inhibitor of Allosteric ErbB Mutation...
    Medical condition: NSCLC, breast cancer, biliary tract cancer, or cervical cancer, any other solid tumors with specific gene mutations
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004864 10065252 Solid tumor LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Prematurely Ended) NL (Prematurely Ended) ES (Completed) IT (Prematurely Ended) PL (Completed)
    Trial results: View results
    EudraCT Number: 2015-001916-37 Sponsor Protocol Number: MATRICS_WP6-1 Start Date*: Information not available in EudraCT
    Sponsor Name:RADBOUD UNIVERSITY MEDICAL CENTER
    Full Title: The neuropsychological characterization of aggressive behaviour in children and adolescents with Conduct Disorder or Oppositional Defiant Disorder (CD/ODD)
    Medical condition: Aggressive behavior in children and adolescents with Conduct Disorder (CD) or Oppositional Defiant Disorder (ODD)
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004873 10037183 Psychic disturbance LLT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2013-003658-26 Sponsor Protocol Number: unknown Start Date*: 2013-11-13
    Sponsor Name:VU University Medical Center
    Full Title: Treat-to-target strategy for early RA patients in usual clinical practice: The COBRA Cohort Study
    Medical condition: Early Active Rheumatoid Arthritis
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed)
    Trial results: (No results available)
    EudraCT Number: 2019-001748-23 Sponsor Protocol Number: SGM-LARRC Start Date*: 2019-08-07
    Sponsor Name:Leiden University Medical Center
    Full Title: Multicenter, open-label, controlled, parallel arms clinical study on the performance of SGM-101, a fluorochrome-labeled anti-carcino-embryonic antigen (CEA) monoclonal antibody, for locally advance...
    Medical condition: Locally advanced rectal cancer Recurrent rectal cancer
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10038038 Rectal cancer PT
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10038046 Rectal cancer recurrent PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2012-005428-14 Sponsor Protocol Number: ISG-STS-TRAB-2012 Start Date*: 2014-04-16
    Sponsor Name:Italian Sarcoma Group
    Full Title: A Phase II study on Trabectedin in advanced retroperitoneal leiomyosarcoma and well differentiated/dedifferentiated liposarcoma
    Medical condition: Advanced retroperitoneal leiomyosarcoma and well differentiated/dedifferentiated liposarcoma
    Disease: Version SOC Term Classification Code Term Level
    16.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10024627 Liposarcoma PT
    16.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10073135 Dedifferentiated liposarcoma PT
    16.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10024189 Leiomyosarcoma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Thu May 30 17:50:53 CEST 2024 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA